ANCA Associated Vasculitis Treated with Ultra-low Dose Rituximab: A Case Report
We reported a case of ANCA-associated vasculitis with pulmonary and renal involvement that was effectively treated with glucocorticoids, cyclophosphamide, and plasma exchange therapy. The patient suffered two infections during maintenance treatment with azathioprine and was later switched to ultralow-dose (100 mg) rituximab to keep the disease in remission. Individualized rituximab therapy is effective in treating ANCA-associated vasculitis, while avoiding excessive immunosuppression, and reducing the financial burden. The diagnosis and treatment of this patient may help clinicians improve their understanding of maintenance therapy for ANCA-associated vasculitis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Xiehe Yixue Zazhi - 14(2023), 6, Seite 1330-1334 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
WU Haiting [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antineutrophil cytoplasmic antibody associated vasculitis |
|---|
| doi: |
10.12290/xhyxzz.2023-0263 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ100173616 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ100173616 | ||
| 003 | DE-627 | ||
| 005 | 20240414070611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240414s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.12290/xhyxzz.2023-0263 |2 doi | |
| 035 | |a (DE-627)DOAJ100173616 | ||
| 035 | |a (DE-599)DOAJ6fb849ead2a74a75b09828f4f62becb5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 0 | |a WU Haiting |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ANCA Associated Vasculitis Treated with Ultra-low Dose Rituximab: A Case Report |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a We reported a case of ANCA-associated vasculitis with pulmonary and renal involvement that was effectively treated with glucocorticoids, cyclophosphamide, and plasma exchange therapy. The patient suffered two infections during maintenance treatment with azathioprine and was later switched to ultralow-dose (100 mg) rituximab to keep the disease in remission. Individualized rituximab therapy is effective in treating ANCA-associated vasculitis, while avoiding excessive immunosuppression, and reducing the financial burden. The diagnosis and treatment of this patient may help clinicians improve their understanding of maintenance therapy for ANCA-associated vasculitis. | ||
| 650 | 4 | |a antineutrophil cytoplasmic antibody associated vasculitis | |
| 650 | 4 | |a rituximab | |
| 650 | 4 | |a azathioprine | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a LI Hang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Xiehe Yixue Zazhi |d Editorial Office of Medical Journal of Peking Union Medical College Hospital, 2021 |g 14(2023), 6, Seite 1330-1334 |w (DE-627)DOAJ078626056 |x 16749081 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:6 |g pages:1330-1334 |
| 856 | 4 | 0 | |u https://doi.org/10.12290/xhyxzz.2023-0263 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/6fb849ead2a74a75b09828f4f62becb5 |z kostenfrei |
| 856 | 4 | 0 | |u https://xhyxzz.pumch.cn/en/article/doi/10.12290/xhyxzz.2023-0263 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1674-9081 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 6 |h 1330-1334 | ||